Seng C. Tang
Amsterdam, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
The E3 ligase COP1 promotes ERα signaling and suppresses EMT in breast cancer.
Journal: Oncogene
Published: May 31, 2021
P-glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain Disposition and Oral Availability of the Novel Taxane Cabazitaxel (Jevtana) in Mice.
Journal: Molecular pharmaceutics
Published: August 29, 2015
P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain and blood disposition of the mTOR Inhibitor everolimus (Afinitor) in mice.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 15, 2014
Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) gene dosage on plasma pharmacokinetics and brain accumulation of dasatinib, sorafenib, and sunitinib.
Journal: The Journal of pharmacology and experimental therapeutics
Published: July 12, 2013
Genetically modified mouse models for oral drug absorption and disposition.
Journal: Current opinion in pharmacology
Published: June 14, 2013
Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
Journal: International journal of cancer
Published: April 12, 2013
Liquid chromatography-tandem mass spectrometric assay for the ALK inhibitor crizotinib in mouse plasma.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
Published: June 08, 2012
P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib.
Journal: The Journal of pharmacology and experimental therapeutics
Published: January 13, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026